Mankind Pharma Ltd
MANKINDMankind Pharma Ltd's earnings have outrun its stock. EPS grew −4.0% in a year against a −6.3% price move.
The sharpest disagreement: Promoters moved −2.2 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a confirmed uptrend (7 weeks in) while the P/E sits at the 62nd percentile of its own 3-year range. Underneath, the last four quarters read improving — profit +31.5% year on year, and 130% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Mankind Pharma Ltd trades at ₹2,484, in a confirmed uptrend and 7 weeks into that stage. That is +6.7% against its own 200-day average. It sits at 73% of a 52-week range of ₹1,999 to ₹2,661. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a confirmed uptrend — week 7 of stage 2, confirmed. At ₹2,484 it trades +6.7% versus its 200-day average and sits at 73% of its 52-week range (₹1,999–₹2,661).
Against the market, two honest reads. Cumulative: over the last 3.2 years the stock moved +78% while the NIFTY 500 moved +51% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 62nd percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Mankind Pharma Ltd trades at 51.4× P/E, mid-range by its own standards (62nd percentile). Its long-run median P/E is 50.4×, measured across 3.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 51.4× is mid-range by its own standards (62nd percentile), against a long-run median of 50.4× measured over 3.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −4.0% against a −6.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +10.9%/yr price move, ~+12.5%/yr came from earnings growth and ~−1.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Mankind Pharma Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −3.7% latest against +49.0% at its 12-quarter best), ROCE slipping at 13.6%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +17.0% | +17.7% | +18.1% | — |
| Profit | −3.6% | +13.9% | +8.4% | — |
| EPS | −4.0% | +13.1% | +8.0% | — |
| Share price | −6.3% | +10.9% | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
43.1/100 — rank 27 of 43 in Pharma - Formulators · 96% evidence confidence
Mankind Pharma Ltd scores 43.1 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 27. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17.5 + 14.1 + 4.4 + 7.1 = 43.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Mankind Pharma Ltd reported ₹3,443 Cr of revenue in the Mar 26 quarter, +11.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 11 years it has compounded at 14.1% a year. The last full year, FY26, came in at ₹14,278 Cr. The last four reported quarters add to ₹14,277 Cr.
Mankind Pharma Ltd reported ₹3,443 Cr of revenue in the Mar 26 quarter, +11.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 11 years it has compounded at 14.1% a year. The last full year, FY26, came in at ₹14,278 Cr. The last four reported quarters add to ₹14,277 Cr.
FY26 revenue came in at ₹14,278 Cr (+17.0% on the year), capping 11 years at 14.1% compound. The latest quarter (Mar 26) printed ₹3,443 Cr, +11.8% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +17.1% growth against the decade's 14.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +17.0% over the last 4 quarters against +17.6%/yr over the last 8 — stabilising; TTM profit −3.7% vs −0.1%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 27.0% this quarter (+5.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Mankind Pharma Ltd's operating margin is 27.0% in the Mar 26 quarter, +5.0 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 18.0% to 27.0%. The current quarter sits inside that band.
Mankind Pharma Ltd's operating margin is 27.0% in the Mar 26 quarter, +5.0 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 18.0% to 27.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 27.0%, +5.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 18.0%–27.0%.
Why the margin moved: operating margin went +4.8 pp year on year while gross margin went +0.6 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins held — did that reach the bottom line? Next: profit +31.5% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Mankind Pharma Ltd earned ₹559 Cr of net profit in the Mar 26 quarter, +31.5% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹1,938 Cr. The 11-year compound rate is 14.3%. That is 16.2% of the quarter's revenue. The same quarter a year earlier earned ₹425 Cr.
Mankind Pharma Ltd earned ₹559 Cr of net profit in the Mar 26 quarter, +31.5% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹1,938 Cr. The 11-year compound rate is 14.3%. That is 16.2% of the quarter's revenue. The same quarter a year earlier earned ₹425 Cr.
Mar 26 profit was ₹559 Cr, +31.5% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹1,938 Cr (−3.6%), and the 11-year compound rate is 14.3%.
Why profit moved: revenue contributed +11.8% and the margin +5.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +0.0% vs revenue +17.1%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 130% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 130% of Mankind Pharma Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹3,121 Cr of operating cash against ₹1,938 Cr of profit. After ₹803 Cr of capital spending, ₹2,318 Cr was left as free cash.
FY26: operating cash of ₹3,121 Cr against reported profit of ₹1,938 Cr, leaving free cash of ₹2,318 Cr after ₹803 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 130% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 130%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 8.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹16,832 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Mankind Pharma Ltd's cash conversion cycle runs 117 days in FY26, down from 125 days in FY21. Capital spending ran ₹16,832 Cr over the last 3 years. At FY26 sales of ₹14,278 Cr each day of that cycle holds about ₹39.1 Cr, so roughly ₹4,577 Cr sits inside the business at any moment.
FY26: debtors at 44 days, inventory at 193 days — roughly 6.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 117 days, tighter than FY21's 125.
The full loop: cash goes out to suppliers and production on day 0; stock waits 193 days to sell; customers pay about 44 days after that; and suppliers themselves are paid at 121 days — netting out to the 117-day cycle.
In money terms: at FY26 sales of ₹14,278 Cr, each day of the cycle holds about ₹39.1 Cr — so the 117-day loop keeps roughly ₹4,577 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹16,832 Cr over the last 3 fiscal years against ₹1,885 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1,128 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 14% and the ROIC − WACC spread is −0.6 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Mankind Pharma Ltd earns a ROCE of 14% in FY26. Return on invested capital clears the cost of that capital by −0.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 13.6% net margin on 0.51× asset turns.
FY26 ROCE is 14%.
🚨 Why the return is what it is — the wiring (FY26): 13.6% net margin × 0.51× asset turns × 1.70× balance-sheet leverage ≈ 11.8% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 11.4% − 12.0% = a −0.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.39.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Mankind Pharma Ltd carries total debt of ₹6,312 Cr against shareholder equity of ₹16,561 Cr as of Mar 26, a debt-to-equity of 0.38. On the annual view that ratio went from 0.14 in FY22 to 0.38 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹6,312 Cr against shareholder equity of ₹16,561 Cr — a debt-to-equity of 0.38. On the annual view, debt-to-equity went from 0.14 (FY22) to 0.38 (FY26). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 5.5 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 5.5 points of Mankind Pharma Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 15.4% of the company. Promoters moved −2.2 points over the same window, to 72.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +5.5 points over 8 quarters to 15.4%; Promoters: −2.2 points over 8 quarters to 72.6%; Foreign institutions: −2.1 points over 8 quarters to 9.4%.
Why the register moved: rotation — foreign institutions −2.1 points against domestic institutions +5.5 points over 8 quarters, with promoters −2.2 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Mankind Pharma Ltd: the Z-score reads 6.62. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 6.62 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 6.62.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Mankind Pharma Ltd this page | 51.4× | ₹1L Cr | Turning around | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Mankind Pharma Ltd's share price today?
Mankind Pharma Ltd trades at ₹2,484, −6.3% over the past year. The company is valued at ₹1,03,546 Cr. The stock sits at 73% of its 52-week range of ₹1,999–₹2,661, +6.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 7 weeks in. — as of 24 July 2026.
What were Mankind Pharma Ltd's latest quarterly results?
Mankind Pharma Ltd reported revenue of ₹3,443 Cr and net profit of ₹559 Cr for the Mar 26 quarter. Revenue rose 11.8% and profit rose 31.5% year on year. Earnings per share were ₹13.43. The operating margin was 27.0%, 5.0 pp higher than a year earlier. — as of 24 July 2026.
What is Mankind Pharma Ltd's revenue?
Mankind Pharma Ltd reported revenue of ₹3,443 Cr in the Mar 26 quarter, +11.8% year on year. For the full FY26 fiscal year, revenue was ₹14,278 Cr (+17.0%). Over the last 11 years revenue compounded at 14.1% a year. — as of 24 July 2026.
What is Mankind Pharma Ltd's profit?
Mankind Pharma Ltd earned ₹559 Cr of net profit in the Mar 26 quarter, +31.5% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹1,938 Cr. The operating margin ran 27.0% in the latest quarter. — as of 24 July 2026.
What is Mankind Pharma Ltd's market cap?
Mankind Pharma Ltd's market capitalisation is ₹1,03,546 Cr at a share price of ₹2,484. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Mankind Pharma Ltd's P/E ratio?
Mankind Pharma Ltd trades at a P/E of 51.4×, at the 62nd percentile of its own 3-year range, against a long-run median of 50.4×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Mankind Pharma Ltd pay a dividend?
Yes — Mankind Pharma Ltd's dividend payout was 2% of profit in FY26, and it recorded a payout in 2 of its last 8 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Mankind Pharma Ltd overvalued?
On its own history, Mankind Pharma Ltd looks mid-range against its own history: its P/E of 51.4× sits at the 62nd percentile of its 3-year range (long-run median 50.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Mankind Pharma Ltd growing?
Yes — Mankind Pharma Ltd is growing: latest-quarter revenue +11.8% year on year, profit +31.5%, and the margin +5.0 pp at 27.0%. The 11-year compound rates are 14.1% (revenue) and 14.3% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Mankind Pharma Ltd performing?
Mankind Pharma Ltd is in a confirmed uptrend, 7 weeks in. Its latest quarter's revenue rose 11.8% and profit rose 31.5% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Mankind Pharma Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −3.7% latest against +49.0% at its 12-quarter best), ROCE slipping at 13.6%. The read comes from the last 12 quarters of growth (revenue growth +17.0% latest, profit growth −3.7% latest, eps growth −5.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Mankind Pharma Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 7 of stage 2), trading +6.7% versus its 200-day average and at 73% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Mankind Pharma Ltd beating the market?
On recent form, yes — Mankind Pharma Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.2 years the stock moved +78% against the NIFTY 500's +51% — ahead of the index over the full window. — as of 24 July 2026.
Will Mankind Pharma Ltd's share price go up?
This page publishes no price forecast for Mankind Pharma Ltd. What it measures instead: the share price is ₹2,484, the price is in a confirmed uptrend 7 weeks in. Its P/E of 51.4× sits at the 62nd percentile of its own 3-year range. — as of 24 July 2026.
Who owns Mankind Pharma Ltd?
Promoters hold 72.6% of Mankind Pharma Ltd, foreign institutions 9.4%, domestic institutions 15.4% and the public 2.5% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 5.5 points over 8 quarters. — as of 24 July 2026.
Does Mankind Pharma Ltd have too much debt?
It is moderate — Mankind Pharma Ltd's debt-to-equity is 0.39, and operating profit covers the interest bill 6×. FY26 borrowings were ₹6,312 Cr against equity of ₹16,300 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Mankind Pharma Ltd's capex?
Mankind Pharma Ltd spent ₹16,832 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹803 Cr, with ₹1,128 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Mankind Pharma Ltd's cash flow?
Mankind Pharma Ltd generated ₹3,121 Cr of operating cash flow in FY26 and ₹2,318 Cr of free cash flow after ₹803 Cr of capital spending. Reported profit that year was ₹1,938 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Mankind Pharma Ltd's profit real cash?
Yes — over the last 3 fiscal years, 130% of Mankind Pharma Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹3,121 Cr against reported profit of ₹1,938 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Mankind Pharma Ltd?
On the balance sheet, the Z-score reads 6.62 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Mankind Pharma Ltd in its business cycle?
Mankind Pharma Ltd's FY26 operating margin was 25.0%, against a 8-year band of 18.0%–27.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 27.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Mankind Pharma Ltd story?
The sharpest disagreement: Promoters moved −2.2 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Mankind Pharma Ltd a stock worth studying right now?
This is not investment advice. The machine read: Mankind Pharma Ltd's earnings have outrun its stock. EPS grew −4.0% in a year against a −6.3% price move. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.